Table 2.

Clinicopathologic characteristics of high-risk patients

	BRCA mutation (N = 158)	BRCAx (N = 815)	Not tested (N = 3520)	p value
Median age [IQR]	40.5 [35.0;51.0]	39.0 [35.0;50.0]	41.0 [37.0;51.0]	< 0.001
Ovary cancer				< 0.001
Yes	7 (4.4%)	15 (1.8%)	16 (0.5%)
No	151 (95.6%)	800 (98.2%)	3504 (99.5%)
Family history				< 0.001
Yes	116 (73.4%)	421 (51.7%)	761 (21.6%)
No	40 (25.3%)	386 (47.4%)	2631 (74.7%)
Unknown	2 (1.3%)	8 (1.0%)	128 (3.6%)
Family history of breast cancer				< 0.001
Yes	103 (65.2%)	403 (49.4%)	667 (18.9%)
No	53 (33.5%)	404 (49.6%)	2725 (77.4%)
Unknown	2 (1.3%)	8 (1.0%)	128 (3.6%)
First-degree relative with breast cancer				< 0.001
Yes	79 (50.0%)	336 (41.2%)	457 (13.0%)
No	76 (48.1%)	471 (57.8%)	2931 (83.3%)
Unknown	3 (1.9%)	8 (1.0%)	132 (3.8%)
T stage				0.527
T1	60 (38.0%)	366 (44.9%)	1472 (41.8%)
T2	83 (52.5%)	376 (46.1%)	1679 (47.7%)
T3	9 (5.7%)	51 (6.3%)	261 (7.4%)
T4	5 (3.2%)	21 (2.6%)	101 (2.9%)
Unknown	1 (0.6%)	1 (0.1%)	7 (0.2%)
N stage				0.603
N0	78 (49.4%)	445 (54.6%)	1955 (55.5%)
N1	47 (29.7%)	226 (27.7%)	963 (27.4%)
N2	19 (12.0%)	90 (11.0%)	402 (11.4%)
N3	13 (8.2%)	52 (6.4%)	183 (5.2%)
Unknown	1 (0.6%)	2 (0.2%)	17 (0.5%)
Histologic grade				< 0.001
1	4 (2.5%)	69 (8.5%)	180 (5.1%)
2	50 (31.6%)	402 (49.3%)	1260 (35.8%)
3	97 (61.4%)	308 (37.8%)	1834 (52.1%)
9	7 (4.4%)	36 (4.4%)	246 (7.0%)
Lymphovascular invasion				0.671
Present	53 (33.5%)	248 (30.4%)	1108 (31.5%)
None	99 (62.7%)	537 (65.9%)	2250 (63.9%)
Unknown	6 (3.8%)	30 (3.7%)	162 (4.6%)
Subtype				< 0.001
HR+/HER2−	75 (47.5%)	488 (59.9%)	1457 (41.4%)
HR+/HER2+	6 (3.8%)	112 (13.7%)	288 (8.2%)
HR−/HER2+	6 (3.8%)	53 (6.5%)	204 (5.8%)
HR−/HER2−	71 (44.9%)	162 (19.9%)	1571 (44.6%)

 IQR interquartile range, HR hormone receptor